Glenmark Pharmaceuticals Ltd vs Neuland Laboratories Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 03, 2026

Key Highlights

The Latest Trading Price of Glenmark Pharmaceuticals Ltd is ₹ 2034 as of 17 Feb 12:23 . The P/E Ratio of Glenmark Pharmaceuticals Ltd changed from 13.5 on March 2021 to 41.5 on March 2025 . This represents a CAGR of 25.18% over 5 yearsThe P/E Ratio of Neuland Laboratories Ltd changed from 33.4 on March 2021 to 59.9 on March 2025 . This represents a CAGR of 12.39% over 5 years The Market Cap of Glenmark Pharmaceuticals Ltd changed from ₹ 13108 crore on March 2021 to ₹ 43458 crore on March 2025 . This represents a CAGR of 27.09% over 5 yearsThe Market Cap of Neuland Laboratories Ltd changed from ₹ 2678 crore on March 2021 to ₹ 15494 crore on March 2025 . This represents a CAGR of 42.05% over 5 years The revenue of Glenmark Pharmaceuticals Ltd for the Dec '25 is ₹ 3945 crore as compare to the Sep '25 revenue of ₹ 6247 crore. This represent the decline of -36.85% The revenue of Neuland Laboratories Ltd for the Dec '25 is ₹ 447.76 crore as compare to the Sep '25 revenue of ₹ 516.07 crore. This represent the decline of -13.24% The ebitda of Glenmark Pharmaceuticals Ltd for the Dec '25 is ₹ 729.88 crore as compare to the Sep '25 ebitda of ₹ 1175 crore. This represent the decline of -37.89% The ebitda of Neuland Laboratories Ltd for the Dec '25 is ₹ 85.19 crore as compare to the Sep '25 ebitda of ₹ 157.35 crore. This represent the decline of -45.86% The net profit of Glenmark Pharmaceuticals Ltd changed from ₹ 340.24 crore to ₹ 403.23 crore over 7 quarters. This represents a CAGR of 10.19% The net profit of Neuland Laboratories Ltd changed from ₹ 97.87 crore to ₹ 40.57 crore over 7 quarters. This represents a CAGR of -39.54% The Dividend Payout of Glenmark Pharmaceuticals Ltd changed from 4.28 % on March 2021 to 4.38 % on March 2025 . This represents a CAGR of 0.46% over 5 yearsThe Dividend Payout of Neuland Laboratories Ltd changed from 8.03 % on March 2021 to 5.97 % on March 2025 . This represents a CAGR of -5.76% over 5 years .

About Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals Limited was incorporated on November 18, 1977.
The Company is actively involved in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity).
It is engaged in the business of development, manufacture and marketing of pharmaceutical products both formulation and active pharmaceuticals ingredients to regulated and semi-regulated markets.
The Company's research and development facilities are located at Mahape, Sinnar and Taloja and manufacturing facilities are located at Nasik, Colvale, Baddi, Nalagarh, Sikkim, Indore and Aurangabad in India. The company has several molecules in various stages of pre-clinical and clinical development primarily focused in the areas of Oncology, Respiratory and Dermatology.
Its branded generics business has a significant presence in markets across emerging economies including India.

About Neuland Laboratories Ltd

Incorporated on January 7, 1984, Neuland Laboratories Limited (NLL) is promoted by Davuluri Sucheth Rao.
The Company is engaged in manufacturing and selling of bulk drugs such as Salbutamol Sulphate, Terbutaline Sulphate, Labetalol Hydrochloride and Ciprofloxacin.
Neuland Drugs & Pharmaceuticals Pvt.
Ltd., a company set up by the same promoters to manufacture bulk drugs was merged with the Company effective from April, 1992.
NLL manufactures bulk drugs. The Company came out with its initial public offering in Apr.'94 at a premium of Rs 35 aggregating Rs 5.69 cr, to part-finance the capacity expansion to manufacture bulk drugs and to diversify its product-mix.

FAQs for the comparison of Glenmark Pharmaceuticals Ltd and Neuland Laboratories Ltd

Which company has a larger market capitalization, Glenmark Pharmaceuticals Ltd or Neuland Laboratories Ltd?

Market cap of Glenmark Pharmaceuticals Ltd is 67,884 Cr while Market cap of Neuland Laboratories Ltd is 19,243 Cr

What are the key factors driving the stock performance of Glenmark Pharmaceuticals Ltd and Neuland Laboratories Ltd?

The stock performance of Glenmark Pharmaceuticals Ltd and Neuland Laboratories Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Glenmark Pharmaceuticals Ltd and Neuland Laboratories Ltd?

As of May 3, 2026, the Glenmark Pharmaceuticals Ltd stock price is INR ₹2405.55. On the other hand, Neuland Laboratories Ltd stock price is INR ₹14998.7.

How do dividend payouts of Glenmark Pharmaceuticals Ltd and Neuland Laboratories Ltd compare?

To compare the dividend payouts of Glenmark Pharmaceuticals Ltd and Neuland Laboratories Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.